ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis

Trial Profile

ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms Compare Absorb
  • Most Recent Events

    • 17 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 03 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top